Int J Clin Exp Med 2015;8(8):12765-12773 www.ijcem.com /ISSN:1940-5901/IJCEM0010182
Original Article Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis Yang Liu1*, Xiaobin Gu1*, Qunying Lin2, Tian Tian1, Lijuan Shao3, Chao Yuan1, Bo Zhang1,4, Kexing Fan1,4 Department of Cancer Center, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China; Department of Respiratory Medicine, Hospital of Putian University, Putian, Fujian, China; 3School of Medicine, Nankai University, Tianjin, China; 4Department of International Joint Cancer Institute, The Second Military Medical University, Shanghai, China. *Co-first authors. 1 2
Received May 13, 2015; Accepted July 3, 2015; Epub August 15, 2015; Published August 30, 2015 Abstract: Backgrounds: Non-small cell lung cancer (NSCLC) is one of the most common malignancies with a high mortality level. Recently, a variety of studies explored the role of osteopontin (OPN) expression in the prognosis of NSCLC, but the results were controversial. Methods: We performed a meta-analysis of eligible studies to evaluate the prognostic significance of OPN expression in NSCLC patients. In order to assess the association between OPN and OS and DFS/PFS, hazard ratio (HR) with 95% confidence interval (CI) was calculated. Results: A total of ten studies comprising 1420 patients were included in the meta-analysis. The summary results indicated that high OPN expression was a poor predictor for OS (HR = 2.19, 95% CI: 1.6-2.98), and DFS/PFS (HR = 2, 95%CI: 1.66-2.41). Subgroup analysis revealed that high OPN expression was a negative prognostic marker for OS and DFS/PFS regardless of ethnicity background, treatment and OPN detection method. Conclusion: Our results showed that increased OPN expression significantly correlated with poor OS and DPS/PFS in NSCLC patients. Keywords: Non-small cell lung cancer, osteopontin, prognosis, biomarker
Introduction Lung cancer is one of the most common malignancies and the leading cause of cancer-related death in the world [1]. Non-small cell lung cancer (NSCLC) constitutes 85% of all lung cancer cases [2]. In spite of multiple treatment methods including surgery, chemotherapy, radiotherapy and targeted therapy have been applied in NSCLC therapies over the past few decades, the prognosis of NSCLC remains dismal with the 5-year survival rate of 50% is considered as a measure of severe heterogeneity. If P≥0.10 in the Q test or I²100 patients and 4 cohorts had
Original Article Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis Yang Liu1*, Xiaobin Gu1*, Qunying Lin2, Tian Tian1, Lijuan Shao3, Chao Yuan1, Bo Zhang1,4, Kexing Fan1,4 Department of Cancer Center, Chinese PLA General Hospital and Chinese PLA Medical School, Beijing, China; Department of Respiratory Medicine, Hospital of Putian University, Putian, Fujian, China; 3School of Medicine, Nankai University, Tianjin, China; 4Department of International Joint Cancer Institute, The Second Military Medical University, Shanghai, China. *Co-first authors. 1 2
Received May 13, 2015; Accepted July 3, 2015; Epub August 15, 2015; Published August 30, 2015 Abstract: Backgrounds: Non-small cell lung cancer (NSCLC) is one of the most common malignancies with a high mortality level. Recently, a variety of studies explored the role of osteopontin (OPN) expression in the prognosis of NSCLC, but the results were controversial. Methods: We performed a meta-analysis of eligible studies to evaluate the prognostic significance of OPN expression in NSCLC patients. In order to assess the association between OPN and OS and DFS/PFS, hazard ratio (HR) with 95% confidence interval (CI) was calculated. Results: A total of ten studies comprising 1420 patients were included in the meta-analysis. The summary results indicated that high OPN expression was a poor predictor for OS (HR = 2.19, 95% CI: 1.6-2.98), and DFS/PFS (HR = 2, 95%CI: 1.66-2.41). Subgroup analysis revealed that high OPN expression was a negative prognostic marker for OS and DFS/PFS regardless of ethnicity background, treatment and OPN detection method. Conclusion: Our results showed that increased OPN expression significantly correlated with poor OS and DPS/PFS in NSCLC patients. Keywords: Non-small cell lung cancer, osteopontin, prognosis, biomarker
Introduction Lung cancer is one of the most common malignancies and the leading cause of cancer-related death in the world [1]. Non-small cell lung cancer (NSCLC) constitutes 85% of all lung cancer cases [2]. In spite of multiple treatment methods including surgery, chemotherapy, radiotherapy and targeted therapy have been applied in NSCLC therapies over the past few decades, the prognosis of NSCLC remains dismal with the 5-year survival rate of 50% is considered as a measure of severe heterogeneity. If P≥0.10 in the Q test or I²100 patients and 4 cohorts had
